acea 1011 has been researched along with jwh-133 in 1 studies
| Studies (acea 1011) | Trials (acea 1011) | Recent Studies (post-2010) (acea 1011) | Studies (jwh-133) | Trials (jwh-133) | Recent Studies (post-2010) (jwh-133) |
|---|---|---|---|---|---|
| 12 | 0 | 1 | 205 | 1 | 148 |
| Protein | Taxonomy | acea 1011 (IC50) | jwh-133 (IC50) |
|---|---|---|---|
| Cannabinoid receptor 2 | Homo sapiens (human) | 0.0818 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fröhlich, K; Schäfer, F; Schmidt, W; Striggow, F; Striggow, V | 1 |
1 other study(ies) available for acea 1011 and jwh-133
| Article | Year |
|---|---|
Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia.
Topics: Animals; Arachidonic Acids; Brain; Brain Infarction; Cannabinoids; Disease Models, Animal; Dose-Response Relationship, Drug; Ectodysplasins; Endocannabinoids; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Indans; Infarction, Middle Cerebral Artery; Leukocyte Common Antigens; Male; Movement Disorders; Neuroprotective Agents; Polyunsaturated Alkamides; Psychomotor Performance; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sulfonic Acids; Time Factors | 2012 |